Introduction
Ras proteins regulate cell fate by cycling between active GTPbound and inactive GDP-bound conformations (Ras-GTP and Ras-GDP). RAS genes encode 4 proteins (N-Ras, H-Ras, K-Ras4A, and K-Ras4B) that have identical guanine nucleotide and effector binding domains but diverge substantially within the hypervariable region (HVR). 1, 2 Prenylation of the C-terminal cysteine and palmitoylation of other cysteines within the HVR of H-Ras and N-Ras induce a dynamic cycle of depalmitoylation and repalmitoylation that regulates subcellular trafficking. By contrast, K-Ras4B localizes to the plasma membrane (PM) by a mechanism that does not involve palmitoylation. 1 Perturbation of palmitate turnover leads to a nonspecific distribution of H-and N-Ras to endomembranes and decreases signaling from the PM. 3 This observation suggests that interfering with depalmitoylation might selectively reduce the growth of cancer cells with NRAS mutations, as normal K-Ras4B function would be preserved. Inhibiting oncogenic N-Ras signaling is particularly relevant in hematologic malignancies where NRAS is mutated more frequently than KRAS. [4] [5] [6] [7] [8] [9] Acyl protein thioesterase 1 (APT1) catalyzes Ras depalmitoylation. 10 Dekker et al 10 recently developed palmostatin B, a small molecule inhibitor with activity against APT1 that disrupted normal H-Ras subcellular localization and attenuated signaling in fibroblasts transformed with oncogenic Hras. Here we present genetic, cell biologic, and biochemical data with in vitro studies of palmostatin B that support targeting the depalmitoylation/ repalmitoylation cycle in hematologic cancers characterized by oncogenic NRAS mutations.
Methods
Nras and Kras alleles containing an N terminal green fluorescent protein (GFP) marker were cloned into the murine stem cell virus (MSCV) vector with expression driven by the internal ribosomal entry site. 11, 12 Retrovirally transduced E14.5 fetal liver cells from inbred C57Bl/6 mice were plated in methylcellulose medium to assess CFU-GM growth as described previously. 1, 11, 12 Biochemical analyses were performed on cultured macrophages that were differentiated from transduced GFP ϩ fetal liver cells in 50 ng/mL M-CSF. 11, 12 Cells were analyzed by confocal microscopy 7 days after differentiation using the Zeiss LSM 510 NLO Meta. Mx1-Cre; LSLNras G12D and Mx1-Cre; LSL-Kras G12D mice were injected with a single dose of polyinosinic-polycytidylic acid to induce Kras/Nras expression as previously described. 13, 14 Bone marrow cells from Mx1-Cre, LSL-Nras G12D and Mx1-Cre, LSL-Kras G12D mice with myeloproliferative disease (MPD) and acute myeloid leukemia (AML) were harvested, and colony assays were performed as described. [14] [15] [16] Mice with MPD were generated in the C57Bl/6 strain background, and the AML cells were generated by insertional mutagenesis in which C57Bl/6 ϫ 129/Sv F1 mice were infected with the MOL4070LTR retrovirus. 14, 15 Palmostatin B was synthesized and suspended as described. 10 
Results and discussion
We generated MSCV vectors encoding N-terminal GFP fusions of wild-type (WT) N-Ras, N-Ras G12D , N-Ras G12D, C181S , and N-Ras G12D, SSDD , which lacks a conserved SSDD (serine-serineaspartic acid-aspartic acid) motif in the HVR domain that promotes stable palmitoylation. 17 After transduction and sorting, CFU-GM growth from GFP ϩ mouse fetal liver cells was assessed over a range of GM-CSF concentrations. In all experiments, the growth of cells infected with an "empty" MSCV-internal ribosomal entry site-GFP vector was also assessed and was consistently similar to cells expressing WT N-Ras (supplemental Figure 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). N-Ras G12D expression induced cytokineindependent CFU-GM growth and conferred pronounced GM-CSF hypersensitivity ( Figure 1A ). Fetal liver cells expressing N-Ras G12D, SSDD formed fewer colonies in the absence of GM-CSF and were less hypersensitive at low cytokine doses ( Figure 1A ). The C181S substitution abrogates the palmitoylation site in the N-Ras HVR. Cells expressing this mutant protein unexpectedly formed fewer CFU-GM colonies than control cells, suggesting dominant negative effects on hematopoietic growth ( Figure 1A) .
We next performed confocal microscopy on macrophages grown from GFP ϩ fetal liver cells. WT N-Ras and N-Ras G12D showed similar distributions to the PM and perinuclear Golgi ( Figure 1B) . Loss of the SSDD motif reduced PM targeting and increased the intensity of perinuclear Golgi staining, whereas the nonpalmitoylated N-Ras G12D, C181S protein showed a complete lack of PM localization ( Figure 1B ).
To analyze Ras signaling, cultured macrophages were deprived of M-CSF and serum for 16 hours followed by stimulation with GM-CSF. Cells expressing WT N-Ras displayed low basal levels of Ras-GTP and phosphorylated ERK (pERK), which increased on GM-CSF stimulation ( Figure 1C ). By contrast, N-Ras G12D and N-Ras G12D, SSDD expression resulted in elevated basal Ras-GTP and pERK levels, which increased further in response to GM-CSF. Although the N-Ras G12D, C181S mutant protein also accumulated in the GTP-bound conformation, basal and cytokine-induced pERK levels were greatly attenuated. Moreover, total Ras levels were markedly lower in macrophages expressing N-Ras G12D, C181S relative to the other 3 proteins ( Figure 1C ). These biochemical data are consistent with the adverse effects of N-Ras G12D, C181S on CFU-GM growth ( Figure 1A ). To further address how N-Ras G12D, C181S expression affects normal Ras signaling and progenitor growth, we generated the C181S mutation in WT N-Ras. This mutant did not alter CFU-GM growth ( Figure 1D ), which supports the hypothesis that GTP-bound N-Ras G12D, C181S functions in a dominant negative manner by sequestering effectors.
To investigate the therapeutic potential of interfering with subcelluar N-Ras G12D localization, we assessed the effects of palmostatin B 10 on the growth of primary hematopoietic cells. We first assayed the effects of palmostatin B on CFU-GM growth from fetal liver cells transduced with GFP-N-Ras G12D and K-Ras4B G12D . Importantly, palmostatin B promoted a dose-dependent reduction in cytokine-independent CFU-GM growth that was selective for cells expressing GFP-N-Ras G12D (Figure 2A ). Similar effects were observed in the presence of a sub-saturating concentration of GM-CSF (0.1 ng/mL; Figure  2A ). We next generated vectors in which the HVR domains of N-Ras G12D and K-Ras4B G12D were exchanged (GFP-N-Ras G12D, KHVR and GFP-K-Ras4B G12D, NHVR ). Studies of progenitors expressing The data presented are from 3 independent experiments. Asterisks on the right panel indicate statistically significant differences in colony growth: *P Ͻ .05; **P Ͻ .005; ***P Ͻ .0005. Cytokineindependent CFU-GM growth was only observed in cells expressing N-Ras G12D, SSDD or N-Ras G12D , and was significantly lower for the SSDD mutant. For statistical analyses, the number of CFU-GM colonies that formed in cells expressing WT N-Ras in the presence of a saturating concentration of GM-CSF (10 ng/mL) was compared with all 3 mutants. Cells expressing N-Ras G12D, SSDD or N-Ras G12D formed significantly more colonies, whereas cells expressing N-Ras G12D, C181S formed significantly fewer. (B) Confocal imaging of macrophages differentiated from GFP ϩ fetal liver cells. Note that the SSDD mutant protein accumulates in the Golgi and that the C181S mutant is absent from the plasma membrane. The confocal images were acquired on the Zeiss LSM 510 NLO Meta using the Plan-APOCHROMAT 63ϫ/1.4 aperture oil objective. Images were taken on live cells grown on Lab-Tek chambered coverglass w/cvr at 25°C. We used GFP as the fluorochrome, and fluorescent signals were detected using photomultiplier tubes. We used the acquisition software LSM 510 and no further manipulation of the images was performed. For personal use only. on May 4, 2017. by guest www.bloodjournal.org From these fusion proteins confirmed the importance of the N-Ras HVR in conferring sensitivity to palmostatin B as cells expressing K-Ras4B G12D, NHVR were highly responsive to the drug, whereas cells transduced with the GFP-N-Ras G12D, KHVR were not ( Figure 2B ).
Confocal microscopy showed that treatment with palmostatin B increased endomembrane localization of N-Ras G12D and K-Ras4B
, whereas PM targeting of K-Ras4B G12D and N-Ras G12D, KHVR was unaffected ( Figure 2C ). Images were taken on live cells grown on Lab-Tek chambered coverglass w/cvr at 25°C. We used GFP as the fluorochrome, and fluorescent signals were detected using photomultiplier tubes. We used the acquisition software LSM 510 and no further manipulation of the images was performed. (D) Effects of palmostatin B on cytokine-independent CFU-GM growth from the bone marrows of 3-month-old Mx1-Cre; LSL-Nras G12D/ϩ , Mx1-Cre; LSL-Kras G12D/ϩ , Mx1-Cre; LSL-Nras G12D/G12D mice as well as from 6-month-old Mx1-Cre, LSL-Nras G12D/G12D mice. One mouse of each genotype was analyzed in 2 independent experiments. Asterisks indicate statistically significant reductions in CFU-GM growth compared with untreated cells of the same genotype: *P Ͻ .05; **P Ͻ .005; ***P Ͻ .0005. (E) Recipient mice that were transplanted with Mx1-Cre, LSL-Nras G12D and Mx1-Cre, LSL-Kras G12D AML cells died of aggressive leukemia (leukocyte counts Ͼ 100 000/mm 3 ). Blast colony growth was assessed from bone marrow cells plated in 10 ng/mL GM-CSF with or without palmostatin B. The growth of CFU-GM colonies from a WT mouse was compared with blast colony growth from the same Kras mutant AML and from 2 Nras AMLs in 2 independent experiments. Asterisks indicate statistically significant reductions in CFU-GM growth compared with untreated cells from the same mice: *P Ͻ .05; **P Ͻ .005.
To evaluate the effects of palmostatin B on cells expressing oncogenic N-and K-Ras from their endogenous loci, we grew CFU-GM colonies from Mx1-Cre, LSL-Nras G12D and Mx1-Cre, LSL-Kras G12D mice. In contrast to Mx1-Cre, LSL-Kras G12D/ϩ mice, 13 heterozygous Nras mutant (Mx1-Cre, LSL-Nras G12D/ϩ ) mice do not develop MPD during the first 6 months of life on an inbred C57Bl/6 strain background, and the bone marrow contains rare cytokine-independent CFU-GM. 14, 18 However, consistent with a recent report, 19 mice that are homozygous for the Nras G12D allele developed overt MPD by 3 months of age (supplemental Figure 3) , and bone marrow cells from these animals and from Mx1-Cre, LSL-Kras G12D/ϩ mice formed large numbers of CFU-GM colonies in the absence of GM-CSF. Palmostatin B reduced cytokineindependent CFU-GM growth from heterozygous and homozygous Nras mutant bone marrow but had no effect on Kras mutant cells ( Figure 2D ). We also cultured cells from Mx1-Cre, LSL-Nras G12D/ϩ and Mx1-Cre, LSL-Kras G12D/ϩ mice that developed AML after retroviral mutagenesis. 14, 15 The growth of blast colonies from 2 independent Nras leukemias was reduced by approximately 50% in response to 30M palmostatin B. Importantly, this drug concentration has no effect on colony growth from a Kras mutant AML or from WT marrow ( Figure 2E ).
Cuiffo and Ren recently reported that mutating the palmitoylation site at cysteine 181 in N-Ras G12D inhibited PM localization in fibroblasts and prevented the development of MPD in a transduction/transplantation model. 20 However, our observation that exogenous expression of the C181S substitution has dominant negative effects in primary progenitors precludes drawing therapeutic inferences from these data. We therefore expressed N-Ras G12D, SSDD and demonstrated that this protein does not interfere with either normal Ras signaling or CFU-GM growth. Importantly, the SSDD mutation reduced N-Ras trafficking to the PM and attenuated the effects of oncogenic N-Ras G12D on progenitor growth. Treatment with palmostatin B had similar effects, and studies in which we created N-Ras and K-Ras4B fusion proteins localized the inhibitory effects to the N-Ras HVR. Palmostatin B also showed selective efficacy in bone marrow cells from mice in which Nras G12D is expressed from the endogenous locus.
Palmostatin B locks N-Ras and H-Ras in the palmitoylated form, which results in entropy-driven diffusion throughout the cell via membrane exchange processes. 21 Developing palmitoyl transferase inhibitors is an alternative strategy for selectively inhibiting oncogenic N-Ras signaling; however, this is challenging because of the existence of more than 20 known family members. 22 Together, our data support investigating inhibitors of depalmitoylation in hematologic cancers characterized by oncogenic NRAS mutations. 
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